Coiled Therapeutics PLC is an oncology company engaged in pursuing opportunities to find new therapies for cancer. The product pipeline of the company consists of AO-252, a novel TACC3 inhibitor currently in Phase I clinical trials in the USA; and STAT-6 siRNA programme for immunology indications. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.
Markedsdata leveret af TwelveData og Morningstar